Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.70) per share. This is a 45.83 percent decrease over losses of $(0.48) per share from the same period last year.
What’s Going On With Molecular Templates Stock?
Molecular Templates shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. Molecular Templates said the findings show that MT-6402 acts uniquely from other approved checkpoint agents and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed. "We are excited to see objective responses in heavily pre-treated, checkpoint-experienced, head and neck cancer patients, a setting with high unmet medical need," said CEO Eric Poma.